Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Vir Biotechnology, Inc.NASDAQ: VIR

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$2.84M, compared with -$114.58M a year earlier. Trailing-twelve-month gross profit was $180.27M. Over 3 fiscal years it compounded at -61.5% a year.

Context

  • Gross profit amounted to 82.9% of revenue in FY2025, down 462.1 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$2.84M or moves back toward the trailing-twelve-month quarterly average of $45.07M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.84M-100.7% QoQ
Last fiscal yearDec 2025
$56.85M+114.1% YoY
LTMMar 2026
$180.27M+137.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+97.5%——
1 year+114.1%——
3-year CAGR-61.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
56.85M USD
Year-over-year change
+114.1%
4-year CAGR
-44.1%

Gross Profit vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +137.1% is the 4th highest of 10, against a peer median of -18.5%.
  • Gross profit amounts to 275.2% of revenue for VIR, versus a peer median of 74.0%.
VIR Competitors
Gross Profit for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.87B EUR-18.5%-46.9%70.8%
MRNAModerna, Inc.LTM Sep 2026$707M USD+166.8%-56.9%28.0%
NVAXNovavax, Inc.LTM Mar 2026$504.72M USD-54.0%+14.8%84.6%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$221.2M USD-59.1%+48.0%23.5%
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.41M USD+1784.1%-29.4%100.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$180.27M USD+137.1%-61.5%275.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$68M USD+5.5%-11.0%98.3%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$54.91M USD+621.8%—77.2%
VALNValneva SELTM Mar 2026€46.05M EUR-46.8%+22.4%29.5%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$40.76M USD-72.9%——
Peer median (excluding VIR) —-18.5%-11.0%74.0%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.